01—Abstract
Summary
Summary of the 8-K filed July 30, 2026. Cited figures are marked; the original filing is the authoritative source.
Guardant Health (GH) reported strong second quarter 2026 results, with total revenue of $335.0 milliona, up 44% year over year from $232.1 million.
The growth was led by Oncology revenue of $219.1 millionb (up 38%, on approximately 63% higher test volume) and a sharp ramp in Screening revenue to $52.9 million from $14.8 million, driven by roughly 66,000 Shield tests versus 16,000 a year earlier. Biopharma & Data grew a more modest 9% to $60.9 million. Non-GAAP gross margin improved to 67% from 66%.
Profitability remains negative and spending is rising. GAAP net loss widened to $120.1 millionc (from $99.9 million), and non-GAAP net loss was $56.2 million, roughly flat year over year. Non-GAAP operating expenses rose to $288.3 million from $215.3 million, reflecting commercial infrastructure and marketing investment behind Shield and Oncology.
Free cash flow was $(69.5) million for the quarter. The company ended June 30, 2026 with about $1.2 billiond in cash, cash equivalents, and restricted cash, though it carries roughly $1.5 billion in convertible senior notes. Management raised 2026 revenue guidance to $1.34–$1.36 billion (36%–38% growth, from $1.30–$1.32 billion).
The raise is driven by Screening, now expected at $218–$230 million on 270,000–285,000 Shield tests. Guidance for non-GAAP operating expenses ($1.08–$1.10 billion) and free cash flow burn ($195–$205 million) was also increased, reflecting accelerated lab capacity investment.
The company held its non-GAAP gross margin guidance at 64%–65%. Investors will likely focus on whether Shield's volume ramp and new coverage can keep pace with rising spending.
02—Key points
Key Highlights
- Total Q2 2026 revenue of $335.0M, up 44% YoY; Screening revenue rose to $52.9M from $14.8M, and Oncology grew 38% to $219.1M.
- Shield screening volume reached about 66,000 tests in Q2 (vs. ~16,000 a year earlier), supported by inclusion in American Cancer Society guidelines and UnitedHealth Group coverage as the first major commercial insurer.
- FY2026 revenue guidance raised to $1.34–$1.36B (36%–38% growth) from $1.30–$1.32B; Oncology volume growth guidance raised to ~50% from ~35%.
- Non-GAAP gross margin of 67% in Q2 (vs. 66%); FY2026 non-GAAP gross margin guidance held at 64%–65%.
- GAAP net loss widened to $120.1M ($0.90/share) from $99.9M; non-GAAP net loss was $56.2M ($0.42/share), roughly flat year over year.
- Non-GAAP operating expense guidance raised to $1.08–$1.10B, and FY2026 free cash flow burn guidance increased to $195–$205M, reflecting accelerated lab capacity investment.
- Cash, cash equivalents, and restricted cash of $1.2B at June 30, 2026, against about $1.5B of convertible senior notes; the company reports a stockholders' deficit of $(222.9)M.
03—Questions
Frequently Asked Questions
What drove the revenue beat and guidance raise?
Screening was the main driver. Shield test volume grew to about 66,000 in Q2 from 16,000, and Screening revenue reached $52.9M. Oncology volume growth of 63% also contributed, with Oncology revenue up 38%. Management raised Screening revenue guidance to $218–$230M from $186–$198M, which accounts for most of the increase in total revenue guidance.
Is Guardant getting closer to profitability?
Not on a GAAP basis. The GAAP net loss widened to $120.1M from $99.9M, mainly due to higher sales and marketing spending and stock-based compensation. Non-GAAP net loss was roughly flat at $56.2M. Non-GAAP operating expenses rose 34% year over year, and management raised its full-year non-GAAP operating expense guidance, so near-term profitability depends on revenue growth outpacing these investments.
How strong is the balance sheet and how much cash does the company burn?
The company had about $1.2B of cash, cash equivalents, and restricted cash at June 30, 2026, and Q2 free cash flow was $(69.5)M. Full-year 2026 free cash flow burn is now guided to $195–$205M, which is an improvement from the $233M burn in 2025. Total stockholders' deficit was $(222.9)M, and about $1.5B of convertible senior notes are outstanding, so refinancing and dilution from those notes remain relevant considerations.
What does the Shield coverage news mean for future growth?
Shield's inclusion in the American Cancer Society's updated colorectal screening guidelines and UnitedHealth Group's coverage decision, the first from a major commercial insurer, are important validation steps. They should support broader access and volume growth. Guidance assumes 270,000–285,000 Shield tests in 2026, so sustaining volume growth and reimbursement will be key to the Screening thesis.
04—Continue